NICE recommends Hepcludex for 'most aggressive and difficult-to-treat form of viral hepatitis'

15 May 2023

The UK's National Institute for Health and Care Excellence (NICE) has recommended the use of Hepcludex (bulevirtide) for the treatment of chronic hepatitis delta virus (HDV) infection on the National Health Service (NHS) in England.

Gilead Sciences’ (Nasdaq: GILD) drug is recommended as an option for treating chronic hepatitis D in adults with compensated liver disease only if there is evidence of significant fibrosis and their hepatitis has either not responded to peginterferon alfa-2a or they cannot have interferon-based therapy.

Despite being the most aggressive form of viral hepatitis, there have historically been severely limited options for people living with this condition. Now, hundreds of eligible patients will now have the option of a treatment that aims to slow or halt the potentially life-threatening consequences.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK